Patient dosing has begun in a phase 2 clinical trial of Aerie Pharmaceuticals’ netarsudil ophthalmic solution for treatment of glaucoma, in accordance with Japan’s Pharmaceuticals and Medical Devices Agency regulations, according to a company press release.
Known as Rhopressa in the United States, netarsudil ophthalmic solution 0.02% has a PDUFA date of Feb. 28, 2018, with the FDA.
The study, which will be conducted in the United States, will include Japanese and Japanese-American subjects. Patients with open-angle glaucoma patients in the study will have baseline IOP of 15 mm Hg to

Full Story →

Patient dosing has begun in a phase 2 clinical trial of Aerie Pharmaceuticals’ netarsudil ophthalmic solution for treatment of glaucoma, in accordance with Japan’s Pharmaceuticals and Medical Devices Agency regulations, according to a company press release.
Known as Rhopressa in the United States, netarsudil ophthalmic solution 0.02% has a PDUFA date of Feb. 28, 2018, with the FDA.
The study, which will be conducted in the United States, will include Japanese and Japanese-American subjects. Patients with open-angle glaucoma patients in the study will have baseline IOP of 15 mm Hg to

Full Story →